Jeffrey Mailhot, MD
Dermatology · Worcester, MANPI 1588722540
Payments from drug & device makers
Across 46 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$322
- LEO Pharma Inc.$170
- Strata Skin Sciences, Inc.$100
- Arcutis Biotherapeutics, Inc.$71
- Pfizer$54
- E.r. Squibb & Sons, L.L.C.$30
- plus $91 from 5 others
What the payments were for
- Food & beverage$82498%
- Education$152%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 18 | $322 |
| LEO Pharma Inc. | 9 | $170 |
| Strata Skin Sciences, Inc. | 6 | $100 |
| Arcutis Biotherapeutics, Inc. | 4 | $71 |
| Pfizer | 3 | $54 |
| E.r. Squibb & Sons, L.L.C. | 1 | $30 |
| UCB, Inc. | 1 | $23 |
| Sanofi | 1 | $20 |
| Incyte Corporation | 1 | $19 |
| Novartis | 1 | $17 |
| Lilly USA, LLC | 1 | $13 |
How this compares
$839 in reported general payments places this provider in the 45th percentile of 552 dermatology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 22 | $560,831 |
| Dupixent SyringeDupilumab | 47 | $226,589 |
| Skyrizi PenRisankizumab-Rzaa | 11 | $222,172 |
| Dupixent PenDupilumab | 33 | $120,859 |
| OtezlaApremilast | 25 | $117,475 |
| Humira(Cf) PenAdalimumab | 12 | $101,581 |
| Clobetasol Propionate | 82 | $5,686 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 73 | $4,575 |
| Ivermectin | 16 | $4,116 |
| Tacrolimus | 24 | $3,355 |
| MethotrexateMethotrexate Sodium | 97 | $3,217 |
| Fluorouracil | 57 | $2,741 |
| Hydroxychloroquine Sulfate | 76 | $2,232 |
| Ketoconazole | 176 | $2,217 |
| Mometasone Furoate | 106 | $1,957 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Worcester
- John HarrisWorcester$17.1M
- Bassel Mahmoud AbdallahWorcester$391K
- Zainab AbbasWorcester$332K
- Mehdi Rashighi FiroozabadiWorcester$277K
- Sarah WhitleyWorcester$130K
- Seth KatesWorcester$64K
- Mark AmsterBrighton$5M
- David GreensteinBeverly$4M
- Alexandra KimballBoston$3.7M
- Robert NossaMarstons Mills$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.